课题基金 / 基金详情

Vascularized tumor explants for drug testing

Vascularized tumor explants for drug testing
用于药物测试的血管化肿瘤外植体
批准号:
10642870
负责人:
Dan Gabriel Duda
金额:
$37.05万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30
关键词:
AccelerationAddressAdjuvantAdjuvant TherapyAnatomyApoptosisAssessment toolBiologicalBiological AssayBiologyBlood VesselsCancer BiologyCancer CenterCell ProliferationCellsChemoresistanceClinicalCoculture TechniquesCollagenCombined Modality TherapyDiagnosisDiseaseDrug ScreeningDrug usageEngineeringExcisionExtracellular MatrixFibroblastsFibronectinsFluorouracilGrowthHarvestHistologicHumanHyaluronanImmunodeficient MouseImplantIn VitroInvestigational TherapiesLeucovorinLocalized DiseaseMaintenanceMalignant NeoplasmsMethodologyMusNeoplasm MetastasisOncologistOperative Surgical ProceduresOxygenPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPerioperativePharmaceutical PreparationsPopulationPostoperative PeriodPrimary NeoplasmProbabilityProliferatingProtocols documentationRecurrenceRegimenResectedRestSamplingScientistSpecimenStromal CellsSystemTechnologyTestingTimeTissue SampleTissuesTumor BiologyTumor TissueTumor-associated macrophagesVascularizationXenograft ModelXenograft procedureanticancer researchcase-by-case basischemotherapyclinically relevantcytotoxicdensitydrug testingeffective therapyexperimental studygemcitabinehigh throughput screeningimprovedin vivoirinotecannovel strategiesoxaliplatinpancreatic ductal adenocarcinoma cellpersonalized cancer therapypredictive toolspreservationpreventprospectiveresponsesecond harmonic generation imagingself assemblysingle-cell RNA sequencingstandard carestandard of caresuccesstooltreatment durationtreatment planningtreatment responsetumortumor growthtumor progressionvascular bed

项目摘要

项目成果

Dan Gabriel Duda的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 我们对癌症进展或对治疗反应的理解将受益于容易获得的,病人- 概括人类肿瘤的生物学和解剖学的特定测定。为此,我们将制定 体外将肿瘤外植体与工程化基质和脉管系统整合的方法学。与适当 在培养条件下,自组装的血管网络发育,然后并入共培养的肿瘤中 从老鼠或病人身上切除。该系统提供了代表性的细胞外基质,相关的基质细胞, 和管腔化血管网络。该方法是直接的并且适合于高通量测定, 使其成为体外药物筛选或指导患者特异性化疗的有吸引力的工具。使用 通过这种方法,我们建议创建一个平台,用于最佳地维持来自胰腺癌患者的样本, 血管化肿瘤外植体(VTE)中的导管腺癌(PDAC)离体用于生物学分析 和药物测试我们将使用小鼠异种移植模型和外科手术来表征VTE并验证该系统。 来自在MGH癌症中心治疗的PDAC患者的组织样品。完成后,该项目将建立 一个强大的、高通量的、经过验证的平台,用于分析肿瘤生物学或药物测试,从而加速 癌症研究和实现癌症的个性化治疗。
英文摘要
Project Abstract Our understanding of cancer progression or response to therapies would benefit from easily accessible, patient- specific assays that recapitulate the biology and anatomy of human tumors. To this end, we will develop methodology for integrating tumor explants with engineered stroma and vasculature in vitro. With appropriate culture conditions, a self-assembled vascular network develops and then incorporates into co-cultured tumors excised from mice or patients. The system provides a representative extracellular matrix, associated stromal cells, and a lumenized vessel network. The methodology is straightforward and amenable to high throughput assays, making it an attractive tool for in vitro drug screening or for the guidance of patient-specific chemotherapies. Using this approach, we propose to create a platform for optimally maintaining samples from patients with pancreatic ductal adenocarcinoma (PDAC) ex vivo in vascularized tumor explants (VTEs) for the purpose of biological analysis and drug testing. We will characterize the VTEs and validate the system using mouse xenograft models and surgical tissue samples from PDAC patients treated at the MGH Cancer Center. When complete, this project will establish a robust, high throughput, and validated platform for analyzing tumor biology or drug testing, thus accelerating cancer research and enabling personalize therapy for cancer.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
血浆生长激素是晚期肝细胞癌患者中对阿托唑珠单抗和贝伐单抗反应的潜在生物标志物。
DOI: 10.18632/oncotarget.28322
发表时间: 2022-12-06
期刊: ONCOTARGET
影响因子: --
作者: [Mohamed, Yehia I, Duda, Dan G, Awiwi, Muhammad O, Lee, Sunyoung S, Altameemi, Lina, Xiao, Lianchun, Morris, Jeffrey S, Wolff, Robert A, Elsayes, Khaled M, Hatia, Rikita I, Qayyum, Aliya, Chamseddine, Shadi M, Rashid, Asif, Yao, James C, Mahvash, Armeen, Hassan, Manal M, Amin, Hesham M, Kaseb, Ahmed Omar]
通讯作者: Kaseb, Ahmed Omar
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer
  • 批准号:
    10512391
  • 项目类别:
  • 资助金额:
    $35.55万
  • 财政年份:
    2023
  • 负责人:
    Dan Gabriel Duda
  • 依托单位:
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
  • 批准号:
    10290575
  • 项目类别:
  • 资助金额:
    $8.37万
  • 财政年份:
    2021
  • 负责人:
    Dan Gabriel Duda
  • 依托单位:
Vascularized tumor explants for drug testing
  • 批准号:
    10317398
  • 项目类别:
  • 资助金额:
    $37.81万
  • 财政年份:
    2021
  • 负责人:
    Dan Gabriel Duda
  • 依托单位:
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
  • 批准号:
    10372211
  • 项目类别:
  • 资助金额:
    $44.33万
  • 财政年份:
    2021
  • 负责人:
    Dan Gabriel Duda
  • 依托单位:
海外基金